To analyze the clinical characteristics and influencing factors of in-hospital pulmonary infections in lung cancer patients during chemotherapy.

74 lung cancer patients admitted to our hospital from March 2022 to March 2024 were selected as the research subjects. The grouping was based on whether hospital acquired lung infections occurred during chemotherapy. The hospital acquired lung infections were the observation group 19 cases and the control group 55 cases. Analyze the distribution and drug resistance of pathogenic bacteria, compare two sets of general data, and perform multivariate analysis using logistic regression.

During chemotherapy, 19 out of 74 patients developed hospital acquired pulmonary infections, with an incidence rate of 25.67%. A total of 27 pathogenic bacteria were isolated, including 17 strains (62.96%) of gram-negative bacteria, 6 strains (22.22%) of gram-positive bacteria, and 4 strains (14.82%) of fungi; The resistance rates of various Gram negative bacteria to ampicillin, ampicillin sulbactam, and compound sulfamethoxazole are all ≥50.00%; Staphylococcus aureus has high resistance to commonly used antibiotics and is most sensitive to penicillin; The age of the observation group, KPS score<80 points before chemotherapy, underlying diseases, ≥2 types of chemotherapy drugs, TNM stage Ⅲ~Ⅳ, invasive procedures, chemotherapy time ≥2 cycles, Alb<35 g/L, Hb<110 g/L, and neutropenia were higher in the control group compared to the control group (P<0.05); Alb<35 g/L、Combining underlying diseases, KPS score<80, invasive procedures Hb<110 g/L, ≥ 2 types of chemotherapy drugs, neutropenia, TNM stages Ⅲ~Ⅳ, and ≥2 cycles of chemotherapy are risk factors for pulmonary infection (P<0.05).

The incidence of pulmonary infection during chemotherapy in lung cancer patients is relatively high, and there are many risk factors. Active prevention and treatment should be taken to reduce the risk of pulmonary infection in patients.